Product Pipeline

Cantab currently has two active anti-infective therapeutic programmes based on its proprietary peptide-derived antibiotics.

Cantab's Gram-negative antibacterial programme concentrates on next generation polymyxins. Polymyxins are one of the few existing antibiotic classes which retain activity against multi-drug resistant strains of key pathogens such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii. With funding from the UK's Biomedical Catalyst programme and the U.S. National Institute of Allergy and Infectious Diseases (NIAID), Cantab is developing new polymyxin derivatives with improved activity and reduced toxicity

NVB333 is under development for systemic treatment of Gram-positive infections such as MRSA. NVB333 is active against strains resistant to currently-available narrow-spectrum antibiotics such as vancomycin, daptomycin and linezolid. NVB333 has been nominated as a drug candidate and is available for licensing for further preclinical and clinical development.